EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Randomized, Placebo‐Controlled, Triple‐Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline‐Based Cancer Therapy

Stephanie Itala Rizk iD, Isabela Bispo Santos da Silva Costa iD, Cecília Beatriz Bittencourt Viana Cruz iD, Brunna Pileggi, Fernanda Thereza de Almeida Andrade, Thalita Barbosa Gonzalez iD, Cristina Salvadori Bittar iD, Julia Tizue Fukushima iD, Vinicius Caldeira Quintao iD, Eduardo Atsushi Osawa iD, Juliana Barbosa Sobral Alves iD, Silvia Moulin Ribeiro Fonseca iD und 15 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.039745 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Stephanie Itala Rizk und 26 weiteren Autor:innen. Beteiligte Einrichtung: Instituto do Coração (InCor), Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo São Paulo SP Brazil. Hauptthemen laut MEDLINE: Ivabradine, Anthracyclines, Sarcoma, Lymphoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer therapy–related cardiac dysfunction frequently occurs in patients receiving anthracycline. Ivabradine reduces heart rate without affecting contractility and showed anti‐inflammatory, antioxidant, and antiapoptotic effects in experimental cardiotoxicity models. This study aims to evaluate the effect of ivabradine on cancer therapy–related cardiac dysfunction in patients with lymphoma or sarcoma treated with anthracycline.

Methods

In a randomized, triple‐blind trial, patients starting anthracycline therapy received either ivabradine 5 mg twice daily or placebo until 30 days after completing treatment. The primary outcome was the incidence of cardiotoxicity measured as a ≥10% relative reduction in global longitudinal strain at 12 months from baseline. Secondary outcomes included 12‐month clinical outcomes, a ≥10% decrease in the left ventricular ejection fraction to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IvabradineAnthracyclinesSarcomaLymphomaVentricular Function, LeftHeart DiseasesAntibiotics, AntineoplasticCardiovascular AgentsHumansMaleFemaleMiddle AgedCardiotoxicityAgedDouble-Blind MethodAdultTreatment OutcomeTroponin TStroke VolumeTime Factors

Stichwörter der Autor:innen

anthracyclinecardiac dysfunctioncardiotoxicityivabradineprevention

Substanzen

IvabradineAnthracyclinesTroponin TAntibiotics, AntineoplasticCardiovascular Agents

Autor:innen und Institutionen

  • Instituto do Coração (InCor), Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo São Paulo SP Brazil.
  • Instituto do Câncer (ICESP), Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo São Paulo SP Brazil.
  • Departamento de Hematologia e Terapia Celular do Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil.
  • Anesthesia and Intensive Care Department IRCCS San Raffaele Scientific Institute Milan Italy.
  • Disciplina de Emergências Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo São Paulo SP Brazil.

ORCID-Profile: Stephanie Itala Rizk, Isabela Bispo Santos da Silva Costa, Cecília Beatriz Bittencourt Viana Cruz, Thalita Barbosa Gonzalez, Cristina Salvadori Bittar, Julia Tizue Fukushima, Vinicius Caldeira Quintao, Eduardo Atsushi Osawa, Juliana Barbosa Sobral Alves, Silvia Moulin Ribeiro Fonseca, Diego Ribeiro Garcia, Juliana Pereira, Valeria Buccheri, Juliana Avila, Lucas Tokio Kawahara, Cecilia Chie Sakaguchi Barros, Lucas Takeshi Ikeoka, Letícia Naomi Nakada, Mariella Fellini, Giovanni Landoni, Ludhmila Abrahão Hajjar

Zitieren

APA

Rizk, S. I., Costa, I. B. S. D. S., Cruz, C. B. B. V., Pileggi, B., de Almeida Andrade, F. T., Gonzalez, T. B., Bittar, C. S., Fukushima, J. T., Quintao, V. C., Osawa, E. A., Alves, J. B. S., Fonseca, S. M. R., Garcia, D. R., Pereira, J., Buccheri, V., Avila, J., Kawahara, L. T., Barros, C. C. S., Ikeoka, L. T., …, & Hajjar, L. A. (2025). Randomized, Placebo‐Controlled, Triple‐Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline‐Based Cancer Therapy. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039745

Vancouver

Rizk SI, Costa IBSDS, Cruz CBBV, Pileggi B, de Almeida Andrade FT, Gonzalez TB, et al. Randomized, Placebo‐Controlled, Triple‐Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline‐Based Cancer Therapy. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.039745

BibTeX
@article{Rizk2025,
  author = {Rizk, Stephanie Itala and Costa, Isabela Bispo Santos da Silva and Cruz, Cecília Beatriz Bittencourt Viana and Pileggi, Brunna and de Almeida Andrade, Fernanda Thereza and Gonzalez, Thalita Barbosa and Bittar, Cristina Salvadori and Fukushima, Julia Tizue and Quintao, Vinicius Caldeira and Osawa, Eduardo Atsushi and Alves, Juliana Barbosa Sobral and Fonseca, Silvia Moulin Ribeiro and Garcia, Diego Ribeiro and Pereira, Juliana and Buccheri, Valeria and Avila, Juliana and Kawahara, Lucas Tokio and Barros, Cecilia Chie Sakaguchi and Ikeoka, Lucas Takeshi and Nakada, Letícia Naomi and Fellini, Mariella and Rocha, Vanderson Geraldo and Rego, Eduardo Magalhães and Hoff, Paulo Marcelo Gehm and Filho, Roberto Kalil and Landoni, Giovanni and Hajjar, Ludhmila Abrahão},
  title = {Randomized, Placebo‐Controlled, Triple‐Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline‐Based Cancer Therapy},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.039745}
}
Kostenlos starten →